Cartesian Therapeutics (RNAC) Long-Term Investments (2015 - 2025)

Cartesian Therapeutics (RNAC) has 11 years of Long-Term Investments data on file, last reported at $2.0 million in Q3 2025.

• Long-Term Investments for Q3 2025 came in at $2.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2025 was $2.0 million (changed 0.0% YoY), and the FY2024 annual result was $2.0 million, changed 0.0% from the prior year.
• Long-Term Investments held at $2.0 million in Q3 2025 per RNAC's latest filing, from $2.0 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $2.0 million in Q3 2021 and troughed at $2.0 million in Q3 2021.
• A 5-year average of $2.0 million and a median of $2.0 million in 2021 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2021 and 2022: Long-Term Investments soared 45.03% in 2021, then changed 0.0% in 2022.
• A 5-year view of Long-Term Investments shows it stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
• Business Quant data shows RNAC's Long-Term Investments at $2.0 million in Q3 2025, $2.0 million in Q2 2025, and $2.0 million in Q1 2025.